Intervacc AB IVACC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- SEK 0.82
- Day Range
- SEK 0.77–0.82
- 52-Week Range
- SEK 0.57–1.46
- Bid/Ask
- SEK 0.77 / SEK 0.78
- Shares Outstanding
- 340.81M
- Market Cap
- SEK 265.15M
- Volume/Avg
- 617,202 / 324,417
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 14.64
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Intervacc AB is a Swedish animal health company that develops, manufactures and commercializes veterinary vaccines based on its proprietary recombinant fusion protein technology platform. Its product, Strangvac, is a vaccine against equine strangles and is marketed across multiple European countries. The company is also developing Piggivac for Streptococcus suis infections in pigs and operates through animal health, veterinary pharmaceuticals and diagnostic services. Geographically, the company generates its revenue from Europe through vaccine sales and distribution partnerships, while expansion targets North America, Australia and New Zealand.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 16
- Website
- https://www.intervacc.se
Valuation
Metric | IVACC |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.14 |
Price/Sales | 14.64 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IVACC |
|---|---|
Quick Ratio | 4.15 |
Current Ratio | 4.51 |
Interest Coverage | — |
Quick Ratio
IVACC
Profitability
Metric | IVACC |
|---|---|
Return on Assets (Normalized) | −29.97% |
Return on Equity (Normalized) | −32.85% |
Return on Invested Capital (Normalized) | −33.71% |
Return on Assets
IVACC
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|%WPLpl! | LOCK|&$fl& | $139B | |||
| Moderna Inc MRNA | LOCK|><R$L%K | LOCK|?nP | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|#txzd@ | LOCK|jsvQ$ | $94B | |||
| argenx SE ADR ARGX | LOCK|NrnLj< | LOCK|#$ | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|V?qK<rj | LOCK|@P | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|##wfQCLz | LOCK|%wYM | $30B | |||
| Incyte Corp INCY | LOCK|nk?mmG^ | LOCK|d# | $24B | |||
| BioNTech SE ADR BNTX | LOCK|r<<?!^t | LOCK|&bY | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|^?>XKLq | LOCK|@JTl^ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|$?fy^%y | LOCK|lRR | $15B |
United States